FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012397598> ?p ?o ?g. }

• W2012397598 endingPage "1337" @default.
• W2012397598 startingPage "1335" @default.
• W2012397598 abstract "To the Editor: Dengue is one of the most widespread infectious diseases globally; transmission now occurs in 128 countries. Although dengue virus (DENV) control strategies have targeted vector control and disease surveillance, the development of an effective vaccine is the holy grail of prevention.Dengue vaccine development has spanned many decades. A candidate vaccine (Sanofi Pasteur, Swiftwater, PA, USA) containing all 4 DENV serotypes is in advanced clinical testing. However, when given to school children in Thailand, this live-attenuated, tetravalent, dengue–yellow fever 17D chimeric virus vaccine showed major but incomplete efficacy against 3 of the 4 DENV serotypes (DENV 1 [61.2%], DENV-3 [81.3%], and DENV-4 [89.9%]) in the intention-to-treat group but no protection against DENV 2, the most pathogenic of the DENV serotypes (1).Two observations from the efficacy trial in Thailand provide insights into protective immunity that could greatly improve second-generation vaccines. The first observation was that a single dose of 4 live-attenuated chimeric DENVs given subcutaneously at a single site failed to raise type-specific protective immunity against the 4 DENV serotypes, and 2) doses 2 and 3 of the Sanofi Pasteur vaccine given to children over a 1-year period failed to improve efficacy outcomes. These results were obtained even though 91% of the children had circulating dengue or Japanese encephalitis antibodies before vaccination, neutralizing antibodies developed to all 4 DENVs, and neutralizing antibody titers increased 2–3 fold after 3 doses of vaccine in 80%–90% of vaccinated children.The inability of a mixture of 4 dengue chimeric viruses to elicit an initial primary neutralizing antibody response in nonhuman primates and susceptible humans was recognized during preclinical testing and explained by the phenomenon of interference (2). Although protective immunity was raised in susceptible rhesus monkeys inoculated with all 4 DENVs at a single site, inoculation of 4 chimeric dengue viruses at 1 or 2 sites did not result in neutralizing antibody responses to all 4 DENV (3). Studies on human primary immune responses to dengue infection have identified critical attachment sites on the virion for neutralizing antibodies (4). Serum samples from children given ≥1 doses of the dengue chimeric vaccine can now be tested for primary neutralizing antibody responses to each of the 4 DENVs. As an alternative, antibody-secreting cells may be isolated and their products identified by using methods as described for dengue-infected children in Nicaragua (5).Infections with 2 different DENVs can protect against severe disease during subsequent infections (6). It has therefore been assumed that persons with DENV neutralizing antibodies are protected against infection. In clinical testing of the Sanofi Pasteur vaccine, failure of multiple booster doses to show protection was unexpected because the children were already substantially immune from prior exposure to DENV or Japanese encephalitis vaccine. When the tetravalent dengue chimeric vaccine was given to partially dengue–immune children and adults in the Philippines, a broad neutralizing antibody response was observed after administration of only 2 vaccine doses (7).We believe that the unanticipated results of the dengue vaccine efficacy trial in Thailand call for new methods of assessing dengue immunity. Myeloid cells are major targets of dengue infection in humans. We and others have described the unique biologic responses when dengue virus–antibody complexes are presented to myeloid cells (8). There is evidence that DENV neutralization titers differ when the same antibodies are assayed in epithelial and Fc-receptor–bearing cells (8). Recent work suggests that primary monocytes and macrophages may not respond in exactly the same fashion to infection by DENV immune complexes (8). Few relevant studies exist in the literature, and most focused on DENV-2. Detailed studies on innate immune responses in human myeloid cells with a variety of dengue immune complexes should proceed forthwith.To our knowledge, only once has an in vitro test correctly predicted which children would be susceptible or have silent infections accompanying a second heterotypic dengue infection (9). This was determined by using serum samples collected before a second dengue infection and testing these serum samples at low dilutions for their ability to protect primary human monocytes from DENV-2 infection or antibody-dependent enhanced infection. During development of the Sanofi Pasteur tetravalent chimeric dengue vaccine, serum samples from vaccinated persons were routinely tested for neutralization of DENV in an epithelial cell line (10). In addition to assaying for antibodies directed at the quaternary site described by de Alwis et al. (4), we suggest that serum samples from vaccinated persons be tested for neutralization of all DENVs in primary human myeloid cells.Although human Fc-receptor cell lines may be convenient for assaying DENV antibodies, decisions regarding their use should be deferred until they are shown to model primary myeloid cells. Because antibody titers often wane after vaccination, the ability of serum samples from vaccinees to protect against infection of myeloid cells with the 4 DENVs should be studied over many years. Changes to in vitro systems for measuring immune responses after dengue vaccination may provide a better surrogate of protection by realigning antibody measurement systems to our contemporary understanding of the pathogenesis of this complex disease." @default.
• W2012397598 created "2016-06-24" @default.
• W2012397598 creator A5015298131 @default.
• W2012397598 creator A5040747937 @default.
• W2012397598 creator A5077156970 @default.
• W2012397598 date "2013-08-01" @default.
• W2012397598 modified "2023-10-12" @default.
• W2012397598 title "Call to Action for Dengue Vaccine Failure" @default.
• W2012397598 cites W1822185265 @default.
• W2012397598 cites W1879379129 @default.
• W2012397598 cites W1922871278 @default.
• W2012397598 cites W1980444528 @default.
• W2012397598 cites W1989767365 @default.
• W2012397598 cites W2017577931 @default.
• W2012397598 cites W2097288560 @default.
• W2012397598 cites W2160653307 @default.
• W2012397598 cites W2466252332 @default.
• W2012397598 doi "https://doi.org/10.3201/eid1908.121864" @default.
• W2012397598 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3739535" @default.
• W2012397598 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23876389" @default.
• W2012397598 hasPublicationYear "2013" @default.
• W2012397598 type Work @default.
• W2012397598 sameAs 2012397598 @default.
• W2012397598 citedByCount "24" @default.
• W2012397598 countsByYear W20123975982014 @default.
• W2012397598 countsByYear W20123975982015 @default.
• W2012397598 countsByYear W20123975982016 @default.
• W2012397598 countsByYear W20123975982017 @default.
• W2012397598 countsByYear W20123975982018 @default.
• W2012397598 countsByYear W20123975982019 @default.
• W2012397598 countsByYear W20123975982020 @default.
• W2012397598 countsByYear W20123975982021 @default.
• W2012397598 countsByYear W20123975982022 @default.
• W2012397598 countsByYear W20123975982023 @default.
• W2012397598 crossrefType "journal-article" @default.
• W2012397598 hasAuthorship W2012397598A5015298131 @default.
• W2012397598 hasAuthorship W2012397598A5040747937 @default.
• W2012397598 hasAuthorship W2012397598A5077156970 @default.
• W2012397598 hasBestOaLocation W20123975981 @default.
• W2012397598 hasConcept C121332964 @default.
• W2012397598 hasConcept C159047783 @default.
• W2012397598 hasConcept C203014093 @default.
• W2012397598 hasConcept C2779308166 @default.
• W2012397598 hasConcept C2779635636 @default.
• W2012397598 hasConcept C2780791683 @default.
• W2012397598 hasConcept C533803919 @default.
• W2012397598 hasConcept C62520636 @default.
• W2012397598 hasConcept C71924100 @default.
• W2012397598 hasConceptScore W2012397598C121332964 @default.
• W2012397598 hasConceptScore W2012397598C159047783 @default.
• W2012397598 hasConceptScore W2012397598C203014093 @default.
• W2012397598 hasConceptScore W2012397598C2779308166 @default.
• W2012397598 hasConceptScore W2012397598C2779635636 @default.
• W2012397598 hasConceptScore W2012397598C2780791683 @default.
• W2012397598 hasConceptScore W2012397598C533803919 @default.
• W2012397598 hasConceptScore W2012397598C62520636 @default.
• W2012397598 hasConceptScore W2012397598C71924100 @default.
• W2012397598 hasIssue "8" @default.
• W2012397598 hasLocation W20123975981 @default.
• W2012397598 hasLocation W20123975982 @default.
• W2012397598 hasLocation W20123975983 @default.
• W2012397598 hasLocation W20123975984 @default.
• W2012397598 hasLocation W20123975985 @default.
• W2012397598 hasOpenAccess W2012397598 @default.
• W2012397598 hasPrimaryLocation W20123975981 @default.
• W2012397598 hasRelatedWork W2005243362 @default.
• W2012397598 hasRelatedWork W2056019569 @default.
• W2012397598 hasRelatedWork W2168704739 @default.
• W2012397598 hasRelatedWork W2186465316 @default.
• W2012397598 hasRelatedWork W2466853895 @default.
• W2012397598 hasRelatedWork W3003968373 @default.
• W2012397598 hasRelatedWork W3019547263 @default.
• W2012397598 hasRelatedWork W3102957462 @default.
• W2012397598 hasRelatedWork W3134718598 @default.
• W2012397598 hasRelatedWork W3099043951 @default.
• W2012397598 hasVolume "19" @default.
• W2012397598 isParatext "false" @default.
• W2012397598 isRetracted "false" @default.
• W2012397598 magId "2012397598" @default.
• W2012397598 workType "article" @default.